The key ICIs in current use consist of monoclonal antibodies targeted to cytotoxic T lymphocyte antigen 4 (anti-CTLA4) and programmed cell death 1/ligand 1 (anti-PD-1/PD-L1), which is a key signaling molecule in immune escape pathways of tumor cells. Here, PDCD1 is linked to neoplasm.